TITLE

Subcommittee looks at Canadian Rx imports

PUB. DATE
May 2003
SOURCE
Employee Benefit News;May2003, Vol. 17 Issue 6, p36
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the response of members of the U.S. House Government Reform Subcommittee on Human Rights and Wellness to the enforcement efforts of the Food and Drug Administration to crack down on businesses facilitating the purchase of Canadian prescription drugs in the country. Accusations against FDA Associate Commissioner William Hubbard; Explanation given by Hubbard to their enforcement efforts.
ACCESSION #
9670044

 

Related Articles

  • Study: U.S. Generic Drugs Cost Less Than Canadian Drugs. Bren, Linda // FDA Consumer;Jul/Aug2004, Vol. 38 Issue 4, p9 

    Relates the findings of a study conducted by the U.S. Food and Drug Administration (FDA) regarding the cost of drugs and the pharmaceutical policy in the U.S. Generic prescription drugs for chronic conditions that were used in the study; U.S. generic drugs that are cheaper than Canadian...

  • Cities vow to maintain Canadian Rx reimports. Gonzalez, Gloria // Business Insurance;2/2/2004, Vol. 38 Issue 5, p4 

    Officials for two the U.S. cities that are currently reimporting prescription drugs from Canada have vowed to continue despite the U.S. Food and Drug Administration's (FDA) latest efforts to curb the practice. In the past six months, the FDA has taken action against at least five companies the...

  • FDA slams governor for buying Canadian. Dickinson, James G. // Medical Marketing & Media;May2004, Vol. 39 Issue 5, p15 

    Reports that the United States Food and Drug Administration (FDA) has criticized New Hampshire Governor Craig Benson for his public endorsement of Canadian drug imports. Benson personally bought them from the CanadaDrugs.com Web site, tested them, and found them to be the same as American drugs;...

  • US FDA's role in halting Canadian drug imports questioned.  // PharmacoEconomics & Outcomes News;6/19/2005, Issue 455, p5 

    Focuses on arguments regarding the role of the U.S. Food and Drugs Administration in stopping Canadian drug imports. Partnership between the agency and the pharmaceutical industry in protecting high prices and profits; Remarks from William K. Hubbard, senior associate commissioner for the agency.

  • Hubbard: Lack of funds to blame for flap over FDA outsourcing. McCarty, Mark // Medical Device Daily;8/28/2007, Vol. 11 Issue 164, p2 

    The article reports on the argument for the outsourcing of the U.S. Food and Drug Administration by former commissioner William Hubbard. Hubbard says that the agency should not be blamed for its intent to outsource some of its administrative function because it is only doing what it can to deal...

  • Update.  // Medical Marketing & Media;May2005, Vol. 40 Issue 5, p16 

    Presents news briefs related to drug policy in the U.S. as of May 2005. Minnesota Attorney General Mike Hatch's testimony in a suicide lawsuit against Pfizer's drug Zoloft; U.S. Food & Drug Adminstration associate commissioner for policy and planning William Hubbard and deputy commissioner for...

  • As I See It. Dickinson, James G. // Medical Marketing & Media;Mar2008, Vol. 43 Issue 3, p16 

    The author reflects on the report about the incapacity of U.S. Food and Drug Administration to intercept contaminated medical imports. He stated that the 5.7% budget increase by the FDA is to be trimmed in the Congress. According to former FDA associate commissioner for policy, William Hubbard...

  • The latest diet pill news. Sullivan, Dana // Glamour;Apr2004, Vol. 102 Issue 4, p102 

    Interviews William K. Hubbard, associate commissioner for policy and planning at the U.S. Food and Drug Administration. Reason behind the ban of ephedra; Availability of the weight loss supplement on the Web; Healthy alternatives for ephedra.

  • UPON CLOSER INSPECTION. Rhea, Shawn // Modern Healthcare;3/30/2009, Vol. 39 Issue 13, p28 

    The article examines the safety initiatives of the U.S. Food and Drugs Administration (FDA) on the shipping of medical products to the U.S. It cites the case of the Ranbaxy Laboratories, which shipped drugs manufactured at its Paonta Sahib plant to the U.S. Safety experts noted that the agency...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics